Background: Oral factor XIa (FXIa) inhibitors may modulate coagulation to prevent
thromboembolic events without significantly increasing bleeding. We explored the pharmacodynamics,
safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention
after acute myocardial infarction (MI).